



Facilitatory Effects of Perineural Dexmedetomidine on Neuraxial and Peripheral Nerve Block

A Meta-Analysis

*Submitted for Partial Fulfillment of Master
Degree in Anesthesiology*

By

Mennatullah Mohamed Sobhy
M.B.B.CH.

Under supervision of

Prof. Dr. Gihan Seif El-Nasr

*Professor of Anesthesiology
Faculty of Medicine – Ain Shams University*

Prof. Dr. Hadeel Magdy Abdel Hamid

*Assistant Professor of Anesthesiology
Faculty of Medicine – Ain Shams University*

Dr. Amr Mohamed Hilal Abdou

*Lecturer of Anesthesiology
Faculty of Medicine – Ain Shams University*

*Faculty of Medicine
Ain Shams University*

2019

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

لَسْبَدَانِكَ لَا عِلْمَ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Gihan Seif El-Masr**, Professor of Anesthesiology Faculty of Medicine – Ain Shams University for her keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Prof. Dr. Hadeel Magdy Abdel Hamid**, Assistant Professor of Anesthesiology Faculty of Medicine – Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Dr. Amr Mohammed Hilal Abdou**, Lecturer of Anesthesiology Faculty of Medicine – Ain Shams University, for his great help, active participation and guidance.*

Mennatullah Mohamed Sobhy

List of Contents

Title	Page No.
List of Tables	i
List of Figures	ii
List of Abbreviations	iv
Introduction	1
Aim of the Work	4
Review of Literature	
▪ Anatomy	5
▪ Techniques	9
▪ Local Anesthetics	17
▪ Adjuvants	23
▪ Pharmacology	27
Methods	36
Results	42
Discussion	53
Conclusion	57
Summary	58
References	59
Arabic Summary	—

List of Tables

Table No.	Title	Page No.
Table (1):	Properties of amides and esters.....	17
Table (2):	Dexmedetomidine: Basic Pharmacokinetic Profile.....	28
Table (3):	Description of the Bromage score.....	40
Table (4):	Main characteristics of included studies.	42

List of Figures

Fig. No.	Title	Page No.
Fig. (1):	Longitudinal section of spinal cord.....	7
Fig. (2):	Anatomical illustration of the brachial plexus with areas of roots, trunks, divisions and cords marked	8
Fig. (3):	Anatomy of the ventebral column	10
Fig. (4):	Correct head position, transducer position, and in-plane needle insertion.....	12
Fig. (5):	White box is area scanned	13
Fig. (6):	Angle formed by the first rib and the subclavian artery	14
Fig. (7):	The structure of dexmedetomidine Dyck, Shafer	29
Fig. (8):	Receptor signaling	30
Fig. (9):	Forest plot showing sensory block duration (intrathecal group).....	43
Fig. (10):	Forest plot showing sensory block duration (supraclavicular group).....	44
Fig. (11):	Forest plot showing motor block duration (Intrathecal group)	44
Fig. (12):	Forest plot showing motor block duration (supraclavicular group).....	45
Fig. (13):	Forest plot showing sensory block onset (Intrathecal group)	45
Fig. (14):	Forest plot showing sensory block onset (supraclavicular group).....	46
Fig. (15):	Forest plot showing motor block onset (Intrathecal group)	47
Fig. (16):	Forest plot showing motor block onset (supraclavicular group).....	47
Fig. (17):	Forest plot: Primary adverse event: bradycardia.....	49

List of Figures (cont...)

Fig. No.	Title	Page No.
Fig. (18):	Forest plot: Primary adverse event: nausea.	49
Fig. (19):	Forest plot: Primary adverse event: hypotension.	50
Fig. (20):	Funnel plot showing sensory block duration.....	51
Fig. (21):	Mean values and SD for time to first analgesic request.	52

List of Abbreviations

Abb.	Full term
ASRA	The American Society of Regional Anesthesia and Pain Medicine
BP	Blood Pressure
BS	Bromage score
CI.....	Confidence Interval
CNS.....	Central Nervous System
CSF	Cerebrospinal Fluid
DXM.....	Dexmedetomidine
DOA	Duration of Analgesia
FDA.....	Food and Drug Administration
HR.....	Heart Rate
ICU.....	Intensive Care Unit
LA.....	Local Anesthetic
LAST.....	Local Anesthetic Systemic Toxicity
MD	Mean difference
NE	Norepinephrine
OR.....	Odds Ratio
SCM	Sternocleidomastoid
SD.....	Standard Deviation
SNS	Sympathetic Nervous System
US	Ultrasound

INTRODUCTION

Dexmedetomidine (DXM) is an anxiety reducing, sedative, and pain medication. It has been used as adjunct to local anesthetics (LAs) to improve the quality of perioperative analgesia and prolong its duration (*Cormack et al., 2005*).

Alpha₂-adrenergic agonists have expanded the horizons of regional anesthesia. DXM is a highly selective α -2 agonist similar to clonidine but with a greater affinity for the α -2 receptor. It is the pharmacologically active d-isomer of medetomidine, a full agonist of α -2 adrenergic receptors (*Gertler et al., 2001*).

In general, presynaptic activation of the α ₂adrenoceptor inhibits the release of norepinephrine, terminating the propagation of pain signals. Postsynaptic activation of α ₂ adrenoceptors in the central nervous system (CNS) inhibits sympathetic activity and thus can decrease blood pressure and heart rate (HR). Combined, these effects can produce analgesia, sedation, and anxiolysis. DXM combines all these effects, thus avoiding some of the side effects of multiagent therapies (*Virtanen et al., 1988*).

DXM was approved in 1999 by the US Food and Drug Administration (FDA) as a short-term sedative and analgesic (<24 hours) for critically ill or injured people on mechanical ventilation in the intensive care unit (ICU). The rationale for its

short-term use was due to concerns over withdrawal side effects such as rebound high blood pressure. However, these effects have not been consistently observed in research studies (*Shehabi et al., 2004*). Since 2004, when it was first used as a LA adjuvant in IV regional anaesthesia, the use of DXM in peripheral nerve blocks have evolved (*Memis et al., 2004*).

DXM is highly lipophilic and thus is rapidly distributed in neural tissues and produces its antinociceptive effects by binding to α_2 receptors in spinal dorsal horn when used neuraxially (*Bajwa et al., 2013*).

One of the highest densities of α_2 receptors has been detected in the locus coeruleus, the predominant noradrenergic nucleus in the brain and an important modulator of vigilance. The hypnotic and sedative effects of α_2 -adrenoceptor activation have been attributed to this site in the CNS. The locus coeruleus is also the site of origin for the descending medullospinal noradrenergic pathway, known to be an important modulator of nociceptive neurotransmission. In this region of the brain, α_2 -adrenergic and opioidergic systems have common effector mechanisms, indicating that DXM has a supraspinal site of action (*MacDonald and Scheinin, 1995*).

In addition to DXM's action in the locus coeruleus of the brain stem, it has been shown to stimulate α_2 receptors directly in the spinal cord, thus inhibiting the firing of nociceptive neurons. The substantia gelatinosa of the dorsal horn of the

spinal cord contains receptors which, when stimulated, inhibit the firing of nociceptive neurons stimulated by peripheral A δ and C fibers and also inhibit the release of the nociceptive neurotransmitter substance P. This spinal mechanism is most likely why DXM is now being used epidurally and intrathecally in addition to its primary use as an intravenous drug (*Tamsen and Gordh, 1984*).

The mechanism by which DXM mediates peripheral nerve blocks is not fully defined. However, there are several hypotheses. It blocks A δ and C fibers and increases potassium conductance in isolated neurons, thus intensifying the LA conduction block. It may also cause local vasoconstriction, thus decreasing LA spread and removal around neural structures. In addition to its α 2A adrenoceptor (*Yoshitomi et al., 2014*).

AIM OF THE WORK

The aim of this study is to evaluate the efficacy of DXM as an adjuvant to local anesthetics for intrathecal and supraclavicular blocks compared to LA alone.

Chapter 1

ANATOMY

Anatomy relevant to subarachnoid blockade:

The spinal cord is continuous with the brain stem proximally and terminates distally in the conus medullaris as the filum terminale (fibrous extension) and the cauda equina (neural extension). This distal termination varies from L3 in infants to the lower border of L1 in adults due to the differential growth rates between the bony vertebral canal and the central nervous system (CNS) (*Miller et al., 2014*).

The spinal canal has a protective sheath composed of three layers. From the outside to the inside they are: dura mater, arachnoid and pia mater (*Figure 1*). These membranes concentrically divide the vertebral canal into three distinct compartments: the epidural, subdural, and subarachnoid spaces (*Snell, 2007*).

The epidural space contains fat, epidural veins, spinal nerve roots, and connective tissue. The subdural space is a potential space between the dura and the arachnoid and contains a serous fluid. The subarachnoid space is traversed by threads of connective tissue extending from the arachnoid mater to the pia mater. It contains the spinal cord, dorsal and ventral nerve roots,

and cerebrospinal fluid (CSF). The subarachnoid space ends at the S2 vertebral level (*Reina et al., 1988*).

Lumbosacral CSF has a constant pressure of approximately 15 cm H₂O, but its volume varies according to the patient because of differences in body habitus and weight. It is estimated that CSF volume accounts for 80% of the variability in peak block height and regression of sensory and motor blockade (*Miller et al., 2014*).

The nerve root is the main site of action for spinal anesthesia. In spinal anesthesia the concentration of LA in CSF is thought to have minimal effect on the spinal cord itself (*Mulroy, 2002*).




Fig. (1): Longitudinal section of spinal cord (*Reina et al., 2000*).

Anatomy relevant to supraclavicular blockade:

The brachial plexus is formed by the ventral rami of C5-C6-C7-C8-T1, occasionally with small contributions by C4 and T2. The block is performed at the level of the distal trunks and origin of the divisions (**Figure 2**), where the brachial plexus is confined to its smallest surface area (*Leffert and Robert, 1985*).

The three trunks carry the entire sensory, motor, and sympathetic innervations of the upper extremity, with the exception of the uppermost part of the medial side of the arm (T2). The densely packed divisions, in contrast, carry a similar